

# Imaging and TOF-SIMS examination on urinary EXTRACELLULAR VESICLES from patients with type I diabetes to determine symptoms of diabetic kidney disease




Magdalena E. Skalska<sup>1,5\*</sup>, Agnieszka Kamińska<sup>2</sup>, Paulina Suduł<sup>3,4</sup>, Tomasz Klupa<sup>3,4</sup>, Maciej Małecki<sup>3,4</sup>, Ewa Ł. Stępień<sup>1,5</sup>

<sup>1</sup>Department of Medical Physics, Marian Smoluchowski Institute of Physics, Institute of Physics, Jagiellonian University in Krakow, Łojasiewicza 11, 30-348 Krakow, Poland; <sup>2</sup>Jerzy Haber Institute of Catalysis and Surface Chemistry, Polish Academy of Science, 30-230 Krakow, <sup>3</sup>Department of Metabolic Diseases, Jagiellonian University Medical College, Jakubowskiego 2 St., 30-688 Krakow, Poland; <sup>4</sup>University Hospital, Jakubowskiego 2 St., 30-688 Krakow, Poland; <sup>5</sup>Centre for Theranostics Jagiellonian University, Kopernika 40 St., 31-501 Krakow, Poland.



email: [magda.skalska@uj.edu.pl](mailto:magda.skalska@uj.edu.pl)



## INTRODUCTION

ToF-SIMS (Time of Flight - Secondary Ion Mass Spectrometry) is a direct and non-destructive technique for analyzing molecules with a mass  $m < 1000$  Da, such as lipids. ToF-SIMS allows for qualitative semi-native testing without isolation, fixation or labelling. An example that can be measured is nanometric **extracellular vesicles (EVs)**, which are becoming increasingly important in diagnosis, treatment and pharmacotherapy. These vesicles undergo changes in their composition and structure, such as **amino acid and lipid profile**, as well as **transported cargo**, which can provide useful information about the onset or presence of disease in the biological system, such as **Chronic Kidney Disease (CKD)**. This disease, in which **kidney damage** is observed, remains a significant clinical issue in both type 1 (T1DM) and type 2 (T2DM) diabetes. There is a need for early markers of kidney damage in these diseases, and one proposed is nanometric urine EVs (uEVs).

In this study, we used ToF-SIMS to compare and evaluate changes in the lipid and amino acids composition of uEVs in urine of people with well-controlled T1DM and healthy people using ToF-SIMS.

## RECRUITMENT OF PATIENTS WITH TYPE 1 DIABETES (T1D) AND CONTROL


uEVs were collected from **33 patients** with T1DM who had good metabolic control (15 years duration, using personal insulin pumps and HbA1C ~ 7%) and **13 healthy individuals**. The patients were recruited from the Department of Metabolic Diseases at Jagiellonian University Medical College.

## uEVs ISOLATION

The uEVs were concentrated and purified using low-pressure filtration, pelleted by ultracentrifugation, and suspended in a PBS solution.

## ToF-SIMS ANALYSIS

The ToF-SIMS (ION-ToF GmbH, Münster, Germany) with a Big<sup>2</sup> LMIG, as a primary ion source was used. Two biological replicates were conducted for an individual EV sample. Data were recorded in the mass range of 0-900 Da for positive ions, collected from three different area in size  $150 \times 150 \mu\text{m}^2$ , for one sample.




## ACKNOWLEDGEMENTS

This work was supported by the SciMat PRA MNS mini-grant the qLife grant funded under the Strategic Programme Excellence Initiative at UJ, from the CMUJ statutory funds (no. N41/DBS/000068) and by the Ministry of Science and Higher Education as a part of pre-implementation research for innovation of the Jagiellonian University (Grant No. N84/DBW/000004 to A. Kamińska. The study was funded by „Laboratories of the Young” as part of the „Excellence - Research University” program at the Jagiellonian University in Kraków (LM/29/SM).

## RESULTS

I STEP - list of characteristic peaks for lipids and amino acids to comparison

1. 508.2949 [C<sub>24</sub>H<sub>48</sub>N<sub>2</sub>O<sub>2</sub>] Ctr 32.2
2. 538.4319 [C<sub>24</sub>H<sub>48</sub>N<sub>2</sub>O<sub>2</sub>] Ctr 34.1
3. 550.2959 [C<sub>24</sub>H<sub>48</sub>N<sub>2</sub>O<sub>2</sub>] Ctr 34.2
4. 568.4746 [C<sub>24</sub>H<sub>48</sub>N<sub>2</sub>O<sub>2</sub>] Ctr 36.0
5. 586.6533 [C<sub>24</sub>H<sub>48</sub>N<sub>2</sub>O<sub>2</sub>] Ctr 36.1
6. 582.4932 [C<sub>24</sub>H<sub>48</sub>N<sub>2</sub>O<sub>2</sub>] Ctr 38.2
7. 622.2666 [C<sub>24</sub>H<sub>48</sub>N<sub>2</sub>O<sub>2</sub>] Ctr 40.1
8. 620.4936 [C<sub>24</sub>H<sub>48</sub>N<sub>2</sub>O<sub>2</sub>] Ctr 40.2
9. 632.2666 [C<sub>24</sub>H<sub>48</sub>N<sub>2</sub>O<sub>2</sub>] Ctr 41.1
10. 632.4936 [C<sub>24</sub>H<sub>48</sub>N<sub>2</sub>O<sub>2</sub>] Ctr 41.3
11. 650.6536 [C<sub>24</sub>H<sub>48</sub>N<sub>2</sub>O<sub>2</sub>] Ctr 42.1
12. 648.5124 [C<sub>24</sub>H<sub>48</sub>N<sub>2</sub>O<sub>2</sub>] Ctr 42.2
13. 648.5038 [C<sub>24</sub>H<sub>48</sub>N<sub>2</sub>O<sub>2</sub>] Ctr 42.3
14. 88.125 [C<sub>24</sub>H<sub>48</sub>N<sub>2</sub>O<sub>2</sub>] arachidonic fragm.
15. 142.0374 [C<sub>24</sub>H<sub>48</sub>N<sub>2</sub>O<sub>2</sub>] Phosphatidylserine fragm.
16. 476.427 [C<sub>24</sub>H<sub>48</sub>N<sub>2</sub>O<sub>2</sub>]NT Sulfone 42.2 fragm.
17. 760.4815 [C<sub>24</sub>H<sub>48</sub>N<sub>2</sub>O<sub>2</sub>]NT Sulfone 18.0 with Na
18. 629.5856 [C<sub>24</sub>H<sub>48</sub>N<sub>2</sub>O<sub>2</sub>]NT GSSL molecular ion
19. 632.2334 [C<sub>24</sub>H<sub>48</sub>N<sub>2</sub>O<sub>2</sub>]NT GSSL molecular ion
20. 634.7363 [C<sub>24</sub>H<sub>48</sub>N<sub>2</sub>O<sub>2</sub>]NT GSSL molecular ion
21. 636.7909 [C<sub>24</sub>H<sub>48</sub>N<sub>2</sub>O<sub>2</sub>]NT GSSL molecular ion
22. 85.0889 [C<sub>24</sub>H<sub>48</sub>N<sub>2</sub>O<sub>2</sub>]NT Chol fragm.
23. 147.4657 [C<sub>24</sub>H<sub>48</sub>N<sub>2</sub>O<sub>2</sub>]NT Chol fragm.
24. 160.8227 [C<sub>24</sub>H<sub>48</sub>N<sub>2</sub>O<sub>2</sub>]NT Chol fragm.
25. 369.4123 [C<sub>24</sub>H<sub>48</sub>N<sub>2</sub>O<sub>2</sub>]NT Chol fragm.
26. 380.7036 [C<sub>24</sub>H<sub>48</sub>N<sub>2</sub>O<sub>2</sub>]NT Chol molecular ion
27. 632.2334 [C<sub>24</sub>H<sub>48</sub>N<sub>2</sub>O<sub>2</sub>]NT GSSL molecular ion
28. 634.7363 [C<sub>24</sub>H<sub>48</sub>N<sub>2</sub>O<sub>2</sub>]NT GSSL molecular ion
29. 636.7909 [C<sub>24</sub>H<sub>48</sub>N<sub>2</sub>O<sub>2</sub>]NT GSSL molecular ion
30. 148.9189 [C<sub>24</sub>H<sub>48</sub>N<sub>2</sub>O<sub>2</sub>]NT a bicyclic fragm.
31. 280.8642 [C<sub>24</sub>H<sub>48</sub>N<sub>2</sub>O<sub>2</sub>]NT a bicyclic fragm.
32. 280.8556 [C<sub>24</sub>H<sub>48</sub>N<sub>2</sub>O<sub>2</sub>]NT a bicyclic fragm.
33. 430.6842 [C<sub>24</sub>H<sub>48</sub>N<sub>2</sub>O<sub>2</sub>]NT a bicyclic molecular ion



II STEP - checking the presence of peaks in spectra

III STEP intensity comparison of characteristic peaks and statistical analysis

We perform statistical analysis by calculating mean values and intensity standard deviations for selected peaks in each group of samples. We determined the significance of differences between the mean values for the groups using Tukey's test and one-way ANOVA. The significance level for the tests was  $p \leq 0.05$ .

Table 1. Demonstrated differences in the percentages of all analyzed lipids and amino acids.

| Group                 | CONTROL [%] | PATIENTS [%] |
|-----------------------|-------------|--------------|
| All lipids (6 groups) | 98.0        | 58.3         |
| Amino acids           | 1.9         | 41.7         |





Table 2. Tested differences in the percentages of individual lipid groups.

| Lipid group          | CONTROL [%] | PATIENTS [%] |
|----------------------|-------------|--------------|
| Fatty acids          | 95.22       | 74.08        |
| Glycerophospholipids | 0.90        | 4.67         |
| Glycerolipids        | 0.03        | 0.29         |
| Sphingolipids        | 0.13        | 15.95        |
| Prenols              | 3.10        | 0.85         |
| Sterols              | 0.63        | 4.17         |



## CONCLUSION

➤ Results have shown that patients with T1DM without CKD exhibit alterations in the content of **specific lipid groups** and changes in the **percentage composition of individual amino acids** in the uEVs compared to the control group.

➤ Urinary Extracellular Vesicles can provide valuable insights into the **pathological processes** occurring in the body of a patient with T1DM, but further research is necessary to determine whether uEVs could serve as a marker for diabetic kidney disease.

WORKFLOW

Graphs showing the values of mean, normalized intensities for all identified, characteristic peaks in positive ionization. Statistically significant differences are \* $p < 0.05$